Clinical Study On The Treatment Of Central Retinal Vein Obstruction Macular Edema By Qizhu Mingmu Lishui Granules Combined With Vitreous Body Injection Of Ranibizumab

Objective: The purpose of this lesson is to explore the effectiveness,durability and safety of Qizhu Mingmu Lishui Granule combined with ranibizumab intravitreal injection in the treatment of macular edema caused by central retinal vein occlusion,and to provide new treatment ideas and methods for macular edema caused by central retinal vein occlusion.Methods: In this study,patients with macular edema due to central retinal vein occlusion diagnosed by Jilin Provincial Hospital of Traditional Chinese Medicine from November 2021 to September 2022 were included in the study by random grouping.A total of 72 cases(72 eyes)were included in the study,including 67 cases(67 eyes),34 cases(34eyes)in the control group and 33 cases(33 eyes)in the treatment group.Within 3 months after enrollment,the patients in the control group received intravitreal injection of ranibizumab once a month,using the 3+PRN scheme,and then ranibizumab injection treatment if necessary,while the patients in the treatment group took oral Qizhu mingmu Lishui granules on this basis to obtain better therapeutic effect.Observe the best corrected visual acuity(BCVA),macular fovea retinal thickness(CMT),repeated injection times and adverse reactions before and after treatment for 3,4,5 and 6 months to evaluate the effectiveness and safety of the treatment.Results: 1.BCVA of patients in both groups at 3,4,5,and 6 months was significantly higher than that before treatment(P1<0.05,P2<0.05);2.Compared with before treatment,the CMT of patients in the two groups significantly increased at 3,4,5,and 6 months after treatment(P<0.05),and there was a significant difference in CMT between the two groups at 3,4,and 6 months after treatment(P<0.05);There was a significant difference in the number of injections between the treatment group and the control group(P<0.05),and the number of injections in the treatment group was significantly lower than that in the control group;4.There was a statistically significant difference in clinical efficacy between the treatment group and the control group after 6 months of treatment(P<0.05).The efficacy of the treatment group(rank mean=29.65)was better than that of the control group(rank mean=38.48);5.None of the patients included in the treatment group experienced significant adverse reactions during the observation period,while two patients in the control group experienced transient elevated intraocular pressure during the treatment period.Conclusion: The treatment of CRVO-ME with Qizhu Mingmu Lishui Granule combined with intravitreal injection of ranibizumab has achieved good results,which can significantly improve the best corrected vision of patients,reduce the thickness of macular fovea,and reduce the number of repeated intravitreal injection of ranibizumab,with high safety,and can be used as a safe and effective treatment plan for CRVO-ME.